Neoadjuvant chemotherapy (NAC) has an important role in the treatment of breast cancer and the need for early detection of treatment response is high. Therefore we investigated the feasibility of using APT CEST at 7T as a biomarker for this purpose. Ten lesions were included and APT signal before and after the first cycle of NAC were correlated to the pathological response. Significant differences were found in APT signal corresponding with the pathological response. These results suggest that APT CEST may be used to predict the response to NAC treatment in an early stage.
This abstract and the presentation materials are available to members only; a login is required.